JBJie Bai

Jie Bai

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Jie Bai has a total of 162 co-authors. Here are the top co-authors by number of shared publications:

  • Yuhui Zhang

    13 shared publications
  • Yuan Zhou

    State Key Laboratory of Experimental Hematology, Institute of Hematology and Hospital of Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, China

    9 shared publications
  • Guangshuai Teng

    8 shared publications
  • Chenxiao Du

    6 shared publications
  • Yuan Zhou

    State Key Laboratory of Experimental Hematology, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, National Clinical Research Center for Blood Diseases, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China

    6 shared publications
  • Lei Zhang

    State Key Laboratory of Experimental Hematology, National Clinical Research Centre for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Tianjin Key Laboratory of Gene Therapy for Blood Diseases, CAMS Key Laboratory of Gene Therapy for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China

    5 shared publications

Latest Publications

  • Open Access

    Spliceosome gene mutations synergize with anthracyclines to amplify atrial fibrillation risk in hematologic malignancies: a multicenter cohort study with discovery and validation

    by Guangshuai Teng, Yuan Zhou, Yuhui Zhang, Ke Shang, Yanjie Lan, Xiaojing Wei, Fuqiang Dong, Gregory Y. H. Lip, Tong Liu, Minghui Duan, et al.

    Background: Atrial fibrillation (AF) is a life‑threatening complication in patients with hematologic malignancies, yet personalized risk stratification remains challenging. Spliceosome gene mutations are key drivers of these malignancies, but their specific role in AF pathogenesis and potential synergy with anthracyclines is unclear. Methods: This retrospective cohort study included a discovery cohort ( n = 1160) and a validation cohort ( n = 412). Multivariable Cox regression, Fine‑Gray competing risk models, and false discovery rate (FDR) correction were used to assess the association between clonal hematopoiesis of indeterminate potential (CHIP)-related mutations (DTA, spliceosome, and DNA damage repair genes) and AF. To avoid immortal time bias, anthracycline exposure was treated as a time-dependent covariate. Interaction analysis was used to evaluate the synergistic effect between spliceosome mutations and anthracyclines. Mechanistic exploration was performed using monocyte‑atrial fibroblast co‑culture and western blotting. Results: In the discovery cohort, spliceosome mutations were significantly associated with AF (sHR = 1.67, 95% CI: 1.09–2.55, FDR q = 0.029). This association remained robust after sensitivity analyses, and was confirmed in the validation cohort (sHR = 6.26, 95% CI: 1.52–25.8, FDR q = 0.022). A significant synergistic interaction was observed between spliceosome mutations and anthracycline exposure: in the discovery cohort, the time‑dependent competing risk model (adjusted for age, sex, disease subtype) yielded an sHR of 3.68 (95% CI: 1.23–10.9, P = 0.019), with consistent results in the validation cohort (sHR = 5.14, 95% CI: 1.29–20.6, P = 0.021). The interaction remained robust in sensitivity analyses. Exploratory analyses showed that patients with spliceosome mutations had larger left atrial diameter and higher monocyte counts (both FDR q < 0.05), with monocyte counts positively correlated with IL‑6 levels. In vitro, monocytes from mutation carriers promoted COL1A1 and α‑SMA expression in atrial fibroblasts, an effect attenuated by IL‑6 neutralization. Conclusions: Spliceosome gene mutations appear to be a novel independent predictor of AF in patients with hematologic malignancies and show a synergistic effect with anthracyclines in increasing AF risk. Myeloid-driven inflammation and atrial remodeling likely contribute to this process. These findings suggest that enhanced AF surveillance could be considered in spliceosome-mutated patients receiving anthracyclines, and that inflammation may represent a potential therapeutic target for cardioprotection.

  • Open Access

    TET2 mutations in myeloproliferative neoplasms: potential mediation of atrial fibrillation by interleukin-1β and impact on stroke risk in clinical cohorts

    by Guangshuai Teng, Minghui Duan, Ke Shang, Yuhui Zhang, Xiaojing Wei, Lan Peng, Gary Tse, Yuan Zhou, Gregory Y.H. Lip, Tong Liu, et al.


  • Open Access

    Dose-optimised recombinant human thrombopoietin versus eltrombopag in patients with immune thrombocytopenia: a multicenter, randomised controlled trial (The TE-ITP Study)

    by Yunfei Chen, Ting Sun, Da Gao, Wei Wang, Zeping Zhou, Guangxun Gao, Yi Wang, Hu Zhou, Yanping Song, Yinghui Lai, et al.


  • Open Access

    Incidence, Outcomes and Risk Factors for Atrial Fibrillation in Patients With JAK2 V617F ‐Positive Myeloproliferative Neoplasms

    by Guangshuai Teng, Ke Shang, Yuhui Zhang, Yifan Duan, Chenxiao Du, Yan Wang, Yanqi Li, Huiqin Zhang, Lan Peng, Xiaojing Wei, et al.

    Background: The incidence, outcomes and risk factors for AF in the JAK2 V617F ‐positive MPN patients are still unknown. Methods: The clinical profiles of patients with JAK2 V617F ‐positive MPN were retrospectively analyzed. Multivariable Cox regression analysis was performed to identify risk factors of AF, thereby developing a risk prediction model. Results: A total of 439 patients were included (age 57 [12–87] years; 51.3% male). AF was associated with higher risks of stroke ( p = 0.036, HR = 1.987, 95% CI 1.047–3.772) and mortality ( p < 0.001, HR = 3.857, 95% CI 1.836–8.103). Multivariable Cox regression showed that TET2 mutation ( p = 0.042, HR = 4.361, 95% CI 1.053–18.056) and increased IL‐1β ( p = 0.012, HR = 5.476, 95% CI 1.547–28.123) were significant risk factors for AF in patients with JAK2 V617F ‐positive MPN. Nomograms were constructed, allowing patients to be categorized into high‐ and low‐risk groups. The 10‐year AF‐free survival rate was significantly lower in the high‐risk group (62% vs. 91.7%; log‐rank test: p = 0.002). The validation cohort confirmed that the survival without AF in the high‐risk group was significantly worse than that in the low‐risk group. The use of either interferon‐α or ruxolitinib, was associated with longer AF‐free survival in the high‐risk group ( p < 0.05). Conclusion: AF was significantly associated with higher risks of stroke and mortality. TET2 mutation and increased IL‐1β were independent risk factors of AF in patients with JAK2 V617F ‐positive MPN.


  • Open Access

    Molecular remission uncoupled with complete haematological response in polycythaemia vera treatment with ropeginterferon alfa‐2b

    by Shanshan Suo, Rong Feng Fu, Albert Qin, Zonghong Shao, Jie Bai, Hu Zhou, Na Xu, Suning Chen, Xuelan Zuo, Xin Du, et al.


  • Targeting BIRC5 as a therapeutic approach to overcome ASXL1-associated decitabine resistance

    by Ming Yao, Xiao Jiang, Fangnan Xiao, Xue Lv, Mengyao Sheng, Wen Xing, Jie Bai, Yuan Zhou


  • Open Access

    Clinical laboratory characteristics and gene mutation spectrum of Ph‐negative MPN patients with atypical variants of JAK2, MPL, or CALR

    by Zhanlong Wang, Xin Tian, Jinyu Ma, Yuhui Zhang, Wenru Ta, Yifan Duan, Fengli Li, Hong Zhang, Long Chen, Shaobin Yang, et al.

    Objective: To evaluate the incidence, clinical laboratory characteristics, and gene mutation spectrum of Ph‐negative MPN patients with atypical variants of JAK2, MPL, or CALR.Methods: We collected a total of 359 Ph‐negative MPN patients with classical mutations in driver genes JAK2, MPL, or CALR, and divided them into two groups based on whether they had additional atypical variants of driver genes JAK2, MPL, or CALR: 304 patients without atypical variants of driver genes and 55 patients with atypical variants of driver genes. We analyzed the relevant characteristics of these patients.Results: This study included 359 patients with Ph‐negative MPNs with JAK2, MPL, or CALR classical mutations and found that 55 (15%) patients had atypical variants of JAK2, MPL, or CALR. Among them, 28 cases (51%) were male, and 27 (49%) were female, with a median age of 64 years (range, 21–83). The age of ET patients with atypical variants was higher than that of ET patients without atypical variants [70 (28–80) vs. 61 (19–82), p = 0.03]. The incidence of classical MPL mutations in ET patients with atypical variants was higher than in ET patients without atypical variants [13.3% (2/15) vs. 0% (0/95), p = 0.02]. The number of gene mutations in patients with atypical variants of driver genes PV, ET, and Overt‐PMF is more than in patients without atypical variants of PV, ET, and Overt‐PMF [PV: 3 (2–6) vs. 2 (1–7), p < 0.001; ET: 4 (2–8) vs. 2 (1–7), p < 0.05; Overt‐PMF: 5 (2–9) vs. 3 (1–8), p < 0.001]. The incidence of SH2B3 and ASXL1 mutations were higher in MPN patients with atypical variants than in those without atypical variants (SH2B3: 16% vs. 6%, p < 0.01; ASXL1: 24% vs. 13%, p < 0.05).Conclusion: These data indicate that classical mutations of JAK2, MPL, and CALR may not be completely mutually exclusive with atypical variants of JAK2, MPL, and CALR. In this study, 30 different atypical variants of JAK2, MPL, and CALR were identified, JAK2 G127D being the most common (42%, 23/55). Interestingly, JAK2 G127D only co‐occurred with JAK2V617F mutation. The incidence of atypical variants of JAK2 in Ph‐negative MPNs was much higher than that of the atypical variants of MPL and CALR. The significance of these atypical variants will be further studied in the future.


  • Open Access

    [Clinical characteristics of myeloid tumors combined with the proliferation of large granular lymphocytes].

    by C X Du, G P Xiang, L Peng, X Y Xiao, G S Teng, Y H Zhang, Y Wang, Y F Duan, Z H Shao, J Bai

    Myeloid neoplasms (MNs) belong to a group of hematological malignancies characterized by the abnormal biological functions of hematopoietic stem progenitor cells. The abnormal immune and hematopoietic microenvironment of patients with MN interact with malignant clonal hematopoietic stem cells, promoting the occurrence and development of their diseases. MN large granular lymphocyte proliferation (MN-LGLP) is a special and rare clinical phenomenon in this type of disease. Currently, research on this disease in domestic and international cohorts is limited. This study analyzes the clinical and laboratory characteristics of this type of patient and explores the impact of LGLP on the clinical characteristics and survival of patients with MN. Patients with MN-LGLP are prone to neutropenia and splenomegaly. The presence of LGLP is not a risk factor affecting the survival of patients with MN-LGLP. STAG, ASXL1, and TET2 are the most common accompanying gene mutations in MN-LGLP, and patients with MN-LGLP and STAG2 mutations have poor prognoses.

    • 8 August 2023
      • Vol. 31  (4) , 1119-1124

    [Clinical Value of Genetic Susceptibility Genes for Myeloid Neoplasm in Myeloproliferative Neoplasm].

    by Shan Gao, Yi-Fan Duan, Yu-Hui Zhang, Guang-Shuai Teng, Chen-Xiao DU, Jie Bai

    To investigate the influence of genetic susceptibility genes for myeloid tumors on the clinical characteristics of patients with myeloproliferative neoplasm (MPN). Two hundred and thirty-two patients with MPN diagnosed at the Second Hospital of Tianjin Medical University from September 2017 to December 2021 were collected, myeloid neoplasm-related genes were detected by targeted next-generation sequencing, and germline mutations were verified. The clinical characteristics and prognosis of MPN patients with germlines mutations in the genetic susceptibility gene for myeloid neoplasm were analyzed. The germline mutation carrier rate of myeloid neoplasm genetic susceptibility gene in MPN patients was 21.6% (50/232), and the PV, ET and PMF patients carrying germline mutations of genetic susceptibility gene for myeloid neoplasm were 25/114 (21.9%), 8/69 (11.6%) and 17/49 (34.7%), respectively, among which PMF patients had the highest carrier rate (P=0.01) and were older (P=0.02). The incidence of chromosomal abnormalities in MPN patients carrying the genetic susceptibitity genes for myeloid neoplasm was higher than that in the non-carrier group (26.5% vs 11.8%, P=0.05). Germline mutations in the genetic susceptibility gene of myeloid neoplasm in MPN patients were mainly concentrated in the RAS pathway, and patients with germline mutations in the genetic susceptibility gene of myeloid neoplasm associated with the RAS pathway had shorter survival without AML progression (PCBL and TP53 germline mutations was shorter than that of non-carrier group (P=0.001; P=0.043). In MPN, PMF patients are more likely to carry germline mutations in the genetic susceptibility gene for myeloid neoplasm. MPN patients with germline mutations carring the genetic susceptibility gene for myeloid neoplasm are prone to chromosomal abnormalities; Patients with MPN who have germline mutations in the genetic susceptibility gene for myeloid neoplasm in the RAS pathway are more likely to develop AML; CBL and TP53 germline mutations affect the overall survival of MPN patients.